Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Monoclonal gammopathy of undetermined significance: an update for nephrologists.

Parry HM, Pratt G, Hutchison CA.

Adv Chronic Kidney Dis. 2012 Sep;19(5):291-6. doi: 10.1053/j.ackd.2012.07.006. Review.

PMID:
22920639
2.

Clinical practice. Monoclonal gammopathy of undetermined significance.

Bladé J.

N Engl J Med. 2006 Dec 28;355(26):2765-70. Review. No abstract available.

PMID:
17192542
3.

Light-chain MGUS: implications for clinical practice.

van Rhee F.

Lancet. 2010 May 15;375(9727):1670-1. doi: 10.1016/S0140-6736(10)60707-6. No abstract available.

PMID:
20472153
4.

[Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].

Guenet L, Decaux O, Lechartier H, Ropert M, Grosbois B.

Rev Med Interne. 2007 Oct;28(10):689-97. Epub 2007 May 25. Review. French.

PMID:
17566612
5.

Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.

Graziani MS, Merlini G.

Expert Rev Mol Diagn. 2014 Jan;14(1):55-66. doi: 10.1586/14737159.2014.864557. Epub 2013 Nov 28. Review.

PMID:
24308339
6.

Monoclonal gammopathies of undetermined significance.

Kyle RA, Rajkumar SV.

Rev Clin Exp Hematol. 2002 Sep;6(3):225-52. Review.

PMID:
12616697
7.

Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma.

Espiño M, Medina S, Blanchard MJ, Villar LM.

Br J Haematol. 2014 Mar;164(5):752-5. doi: 10.1111/bjh.12679. Epub 2013 Nov 22. No abstract available.

PMID:
24261626
8.

Diagnosis of monoclonal gammopathy of renal significance.

Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH; International Kidney and Monoclonal Gammopathy Research Group..

Kidney Int. 2015 Apr;87(4):698-711. doi: 10.1038/ki.2014.408. Epub 2015 Jan 21. Review.

PMID:
25607108
9.

Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.

Kaplan B, Golderman S, Aizenbud B, Esev K, Kukuy O, Leiba M, Livneh A, Ben-Zvi I.

Am J Hematol. 2014 Sep;89(9):882-8. doi: 10.1002/ajh.23773. Epub 2014 Jun 27.

10.

Fibrillary glomerulopathy secondary to light chain deposition disease in a patient with monoclonal gammopathy.

Sundaram S, Mainali R, Norfolk ER, Shaw JH 4th, Zhang PL.

Ann Clin Lab Sci. 2007 Autumn;37(4):370-4.

PMID:
18000296
11.

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM; European Myeloma Network..

Haematologica. 2014 Jun;99(6):984-96. doi: 10.3324/haematol.2013.100552. Epub 2014 Mar 21. Review.

12.

[Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis].

Hübel K, Hallek M.

Internist (Berl). 2013 Jun;54(6):709-14. doi: 10.1007/s00108-012-3215-2. German.

PMID:
23670732
13.

Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany.

Eisele L, Dürig J, Hüttmann A, Dührsen U, Assert R, Bokhof B, Erbel R, Mann K, Jöckel KH, Moebus S; Heinz Nixdorf Recall Study Investigative Group..

Ann Hematol. 2012 Feb;91(2):243-8. doi: 10.1007/s00277-011-1293-1. Epub 2011 Jul 26.

PMID:
21789623
14.
15.

Monoclonal gammopathy: significance and possible causality in renal disease.

Paueksakon P, Revelo MP, Horn RG, Shappell S, Fogo AB.

Am J Kidney Dis. 2003 Jul;42(1):87-95.

PMID:
12830460
16.

Free light-chains and renal disorders: when small is worse.

Hutchison CA, Pratt G.

Lancet. 2010 Oct 9;376(9748):1220; author reply 1221-2. doi: 10.1016/S0140-6736(10)61873-9. No abstract available.

PMID:
20934588
17.
18.

Screening panels for detection of monoclonal gammopathies: confidence intervals.

Pretorius CJ, Ungerer JP, Wilgen U, Klingberg S.

Clin Chem. 2010 Apr;56(4):677-9; author reply 679-80. doi: 10.1373/clinchem.2009.139097. Epub 2010 Jan 28. No abstract available.

19.

UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).

Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D'Sa S, Soutar R, Waage A, Gulbrandsen N, Gregersen H, Low E; Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group..

Br J Haematol. 2009 Oct;147(1):22-42. doi: 10.1111/j.1365-2141.2009.07807.x. Epub 2009 Aug 10. No abstract available. Erratum in: Br J Haematol. 2010 Feb;148(3):491.

PMID:
19673884
20.

Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge.

Nambirajan A, Bhowmik D, Singh G, Agarwal SK, Dinda AK.

Transpl Int. 2015 Mar;28(3):375-9. doi: 10.1111/tri.12497. Epub 2014 Dec 16.

Supplemental Content

Support Center